Development of drugs for the treatment of Alzheimer’s disease is a
work in progress. Over the past couple decades, many novel therapeutic agents
have been developed and tested. However, not many of them made it to the
clinical level. Hence, researchers are constantly in search of newer and better
methods that may one day lead to the development of more advanced and effective
therapeutic regimes.
 |
| Alzheimer’s disease |
One of the most recent methods that may help in screening natural
and synthetic compounds is the in silico method of cross docking. A recent
study based on the same approach screened flavonoids and xanthonoids and found
that luteolin works best against many Alzheimer specific protein targets viz:
CDK5/p25.
No comments:
Post a Comment